Top Markets
#1 Zora Zora +31.68%
#2 AI XOVIA AI XOVIA +30.82%
#3 Full Moon Full Moon +18.72%
#4 0G 0G +17.40%
#5 Notcoin Notcoin +16.40%
#6 Wrapped NXM Wrapped NXM +11.91%
#7 rsERG rsERG +11.83%
#8 Seeker Seeker +10.75%
#9 Axelar Axelar +10.62%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +10.43%
Coin of the day
Zora Zora
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Eikon Therapeutics, Inc. Common Stock Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc. Common Stock

EIKN
Rang in Aktien #12325
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established... Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Aktienkurs
$11.03
Zuletzt synchronisiert: 2026-08-28
Marktkapitalisierung
$597.15M
Veränderung (1 Tag)
-4.25%
Veränderung (1 Jahr)
-
Land
US
Handel Eikon Therapeutics, Inc. Common Stock (EIKN)

Kategorie

Healthcare
P/B-Verhältnis für Eikon Therapeutics, Inc. Common Stock (EIKN)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Eikon Therapeutics, Inc. Common Stock beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Eikon Therapeutics, Inc. Common Stock von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH